{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:03:19Z","timestamp":1792342999968,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018313","name":"Cleveland Eye Bank Foundation","doi-asserted-by":"publisher","award":["P30EY025585"],"award-info":[{"award-number":["P30EY025585"]}],"id":[{"id":"10.13039\/100018313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007312","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012729","name":"Case Western Reserve University Clinical and Translational Science Collaborative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ophtha.2025.01.016","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:02:44Z","timestamp":1737658964000},"page":"748-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-9781","authenticated-orcid":false,"given":"Kevin C.","family":"Allan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1299-8144","authenticated-orcid":false,"given":"Julia H.","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4827-6906","authenticated-orcid":false,"given":"Sonia","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-669X","authenticated-orcid":false,"given":"Jacqueline","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-9515","authenticated-orcid":false,"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra V.","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/npjamd.2016.3","article-title":"A glimpse at the aging eye","volume":"2","author":"Lin","year":"2016","journal-title":"npj Aging Mech Dis"},{"issue":"5","key":"10.1016\/j.ophtha.2025.01.016_bib3","doi-asserted-by":"crossref","first-page":"108271","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ophtha.2025.01.016_bib4","doi-asserted-by":"crossref","first-page":"100916","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in Glaucoma: From the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.ophtha.2025.01.016_bib5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.drudis.2022.05.026","article-title":"Drug repurposing: An effective strategy to accelerate contemporary drug discovery","volume":"27","author":"Zhan","year":"2022","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.ophtha.2025.01.016_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1167\/iovs.18-26422","article-title":"The common antidiabetic drug metformin reduces odds of developing age-related macular degeneration","volume":"60","author":"Brown","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ophtha.2025.01.016_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.64.11.22","article-title":"Association of metformin and other diabetes medication use and the development of new-onset dry age-related macular degeneration: a case-control study","volume":"64","author":"Kaufmann","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jamaophthalmol.2023.5478","article-title":"Metformin use and age-related macular degeneration in patients without diabetes","volume":"142","author":"Aggarwal","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2025.01.016_bib9","doi-asserted-by":"crossref","first-page":"e83759","DOI":"10.1371\/journal.pone.0083759","article-title":"Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration","volume":"8","author":"Guymer","year":"2013","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.ophtha.2025.01.016_bib10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ophtha.2025.01.016_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ophtha.2025.01.016_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ophtha.2025.01.016_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ophtha.2025.01.016_bib15","article-title":"Potential Indications for GLP-1 receptor agonists keep expanding","volume":"2023","author":"Allan","year":"2023","journal-title":"NEJM Journal Watch"},{"issue":"13","key":"10.1016\/j.ophtha.2025.01.016_bib16","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.01.016_bib17","first-page":"31","article-title":"Potential roles of glucagon-like peptide-1 and its analogues in dementia targeting impaired insulin secretion and neurodegeneration","volume":"12","author":"Mehan","year":"2022","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.ophtha.2025.01.016_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2025.01.016_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaophthalmol.2024.1584","article-title":"Effect of low-dose aspirin on the course of age-related macular degeneration: a secondary analysis of the ASPREE randomized clinical trial","volume":"142","author":"Robman","year":"2024","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.01.016_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2025.01.016_bib22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.ophtha.2025.01.016_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.oret.2024.01.026","article-title":"Propensity-matched analysis of the risk of age-related macular degeneration with systemic immune-mediated inflammatory disease.","volume":"8","author":"Shukla","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2025.01.016_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001154","article-title":"Subretinal drusenoid deposits are strongly associated with coexistent high-risk vascular diseases","volume":"7","author":"Ledesma-Gil","year":"2022","journal-title":"BMJ Open Ophth"},{"issue":"3","key":"10.1016\/j.ophtha.2025.01.016_bib27","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1167\/iovs.15-18637","article-title":"Overweight, obesity, and risk of age-related macular degeneration","volume":"57","author":"Zhang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100341","article-title":"Systemic dyslipidemia in age-related macular degeneration: an updated systematic review and meta-analysis","volume":"4","author":"Li","year":"2024","journal-title":"Ophthalmology Science"},{"issue":"11","key":"10.1016\/j.ophtha.2025.01.016_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110942","article-title":"Inflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction","volume":"39","author":"Sterling","year":"2022","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.ophtha.2025.01.016_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41418-022-01062-4","article-title":"Cell death and inflammation during obesity: \u201cKnow my methods, WAT(son).\u201d","volume":"30","author":"Hildebrandt","year":"2023","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.ophtha.2025.01.016_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2015.1440","article-title":"Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus","volume":"133","author":"Lin","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"0","key":"10.1016\/j.ophtha.2025.01.016_bib32","article-title":"Comparative effects of GLP-1 receptor agonists and metformin on glaucoma risk in type 2 diabetes patients","volume":"0","author":"Muayad","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2025.01.016_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.01.016_bib34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/ijms22031296","article-title":"Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Vessels","volume":"22","author":"Ruan","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2014.07.051","article-title":"Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis","volume":"122","author":"Zhao","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2025.01.016_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.ophtha.2025.01.016_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41433-019-0393-3","article-title":"Socio-economic status and outcomes for patients with age-related macular degeneration","volume":"33","author":"More","year":"2019","journal-title":"Eye (Lond)"},{"issue":"19","key":"10.1016\/j.ophtha.2025.01.016_bib38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein + Zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease Study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","journal-title":"JAMA"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:46:21Z","timestamp":1774417581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0161642025000703"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.01.016","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}